Showing 2181-2190 of 2527 results for "".
- Alcon Announces FDA Approval of the OTC Switch of Pataday Once Daily Relief Extra Strengthhttps://modernod.com/news/alcon-announces-fda-approval-of-the-otc-switch-of-pataday-once-daily-relief-extra-strength/2478016/Alcon announced that Pataday Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%), formerly prescribed as Pazeo, has been approved by the FDA for sale over-the-counter (OTC) in the United States. Pataday Once Daily Relief Extra Strength is the first and only once
- Sensible Medical Announces Partnership Aimed at Restoring Confidence for Safe Surgery During COVID-19https://modernod.com/news/sensible-medical-announces-partnership-aimed-at-restoring-confidence-for-safe-surgery-during-covid-19/2478015/Sensible Medical has announced exclusive distribution rights for the United States and Canada of Toul Meditech’s Operio Mobile and SteriStay Clean Air Zone Systems for surgery and special procedures. The ultraclean H14 filtration system creates laminar airflow at the surgical site, protec
- Searchable Contact Lens Database Launched in U.S.https://modernod.com/news/searchable-contact-lens-database-launched-in-u-s/2478010/For the first time, the searchable contact lens database for eye care practitioners—the Contact Lens Compendium—is accessible in the United States. With the launch of the U.S. version (https://compendium.contactlensupdate.com/us), ECPs now
- OCT Angiography Demonstrates Retinal Involvement in Amblyopiahttps://modernod.com/news/oct-angiography-demonstrates-retinal-involvement-in-amblyopia/2478003/Optical coherence tomography angiography (OCT-A) could play a role in diagnosing and understanding the pathogenesis of amblyopia, researchers in Hong Kong report, according to a Reuters report. “Our study, utilizing high-reso
- Regeneron Advances Double Antibody Cocktail Into Phase 3 COVID-19 Prevention Studyhttps://modernod.com/news/regeneron-kicks-off-prevention-trial-for-covid-19-antibody-cocktail/2477979/Regeneron Pharmaceuticals announced the start of a phase 3 study investigating the ability of the double antibody cocktail REGN-COV2 to prevent infection among uninfected people who have had close exposure to a COVID-19 patient, according to a FirstWord Pharma report. The company added that REGN-
- Moderna Reiterates July Start for Phase 3 COVID-19 Vaccine Trial Following Report of Delayhttps://modernod.com/news/moderna-reiterates-july-start-for-phase-3-covid-19-vaccine-trial-following-report-of-delay/2477967/Shares in Moderna fell as much as 9.4% on Thursday after a report indicated that the company’s late-stage trial for potential COVID-19 vaccine mRNA-1273 will be delayed. According to the report in STAT News citing unnamed investigators involved in running the trial, which was slated to begin July
- Remdesivir, the First Coronavirus Drug, Gets a Price Taghttps://modernod.com/news/remdesivir-the-first-coronavirus-drug-gets-a-price-tag/2477953/Remdesivir, the first drug shown to be effective against the coronavirus, will be distributed under an unusual agreement with the federal government that establishes nonnegotiable prices and prioritizes American patients, health officials announced on Monday, accordin
- Santen and Singapore’s Health-Tech Start-up, Plano, Form a Strategic Alliance to Tackle the Global Burden of Myopiahttps://modernod.com/news/santen-and-singapores-health-tech-start-up-plano-form-a-strategic-alliance-to-tackle-the-global-burden-of-myopia/2477947/Santen Pharmaceutical and Plano announced a strategic alliance to tackle the global burden of myopia. Under the alliance, Plano has secured an investment from Santen with the goal of tackling the burden of myopia using both a holistic approach and innovative technological solutions. “
- Epipole Raises $1.9 million, Appoints Former Optos Exec as Chairmanhttps://modernod.com/news/epipole-raises-1-9-million-appoints-former-optos-exec-as-chairman/2477943/Video retinal imaging company Epipole announced that it has secured £1.5 million ($1.9 million) in new funding to prepare for introduction into the United States ophthalmic imaging market. Epipole’s patented technology enables clinicians to scan the retina using real-time video and then e
- The FDA Does Not Approve Allergan’s Wet AMD Drug Candidate Abicipar Pegolhttps://modernod.com/news/allergan-and-molecular-partners-receive-complete-response-letter-from-fda-on-biologics-license-application-for-abicipar-pegol/2477937/Citing an unfavorable benefit-risk ratio, the FDA rejected Allergan and co-developer Molecular Partners’ wet AMD drug candidate Abicipar pegol. The FDA issued a complete response letter to the biologics license application (BLA) for Abicipar pegol, a novel, investigational DARPin the